NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.48 Bn | 176.19 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 129.11 Bn | 126.23 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.35 Bn | 99.13 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.68 Bn | 67.22 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 48.35 Bn | 44.67 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.38 Bn | 27.26 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.04 Bn | 25.76 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.92 Bn | 26.35 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | 122.43% |
| 10 | NeuroPace | 518.23 Mn | 464.25 Mn | 18.05 Mn | 21.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.33% |
| Dec 31, 2025 | 110.64% |
| Sep 30, 2025 | -9.03% |
| Jun 30, 2025 | 47.35% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | -42.42% |
| Sep 30, 2024 | 22.96% |
| Jun 30, 2024 | 10.77% |
| Mar 31, 2024 | 22.66% |
| Dec 31, 2023 | 58.09% |
| Sep 30, 2023 | 66.79% |
| Jun 30, 2023 | 58.86% |
| Mar 31, 2023 | 14.93% |
| Dec 31, 2022 | 4.01% |
| Sep 30, 2022 | -56.56% |
| Jun 30, 2022 | -76.86% |
| Mar 31, 2022 | -93.22% |
| Dec 31, 2021 | -27.99% |
| Sep 30, 2021 | 18.07% |
| Jun 30, 2021 | -83.33% |